Juli P. Miller (Adaptimmune Therapeutics plc (Nasdaq: ADAP))

Miller, Juli P. (Adaptimmune 201808 Director Investor Relations)

	Organisation	Adaptimmune Therapeutics plc (Nasdaq: ADAP)
	Group	Adaptimmune (Group)
	Product	public relations / investor relations / marcom (services)
	Product 2	SPEAR™ T-cell therapy

Record changed: 2024-10-12

Picture Swiss Biotech Association Swiss Biotech Days 2025 SBD25 Basel 650x200px

More documents for Juli P. Miller

[1] Adaptimmune Therapeutics plc. (8/1/24). "Press Release: Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor". Philadeliphia, PA & Oxford....
[2] Adaptimmune Therapeutics plc. (11/8/22). "Press Release: Adaptimmune Reports Third-Quarter Financial Results and Business Update". Philadelphia, PA & Oxford....
[3] Adaptimmune Therapeutics plc. (10/25/22). "Press Release: Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK". Philadelphia, PA & Oxford....
[4] Adaptimmune Ltd.. (10/5/19). "Press Release: United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4". Philadeliphia, PA & Oxfordshire....
[5] Adaptimmune Ltd.. (9/30/19). "Press Release: Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO". Philadeliphia, PA & Oxfordshire....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]